Small molecule · Inhibitor of spleen tyrosine kinase (SYK) · developed by Calithera Biosciences
Phase 1Most advanced trial (none active)
1Registered trials
What is Mivavotinib?
Mivavotinib is an inhibitor of spleen tyrosine kinase (SYK), a B-cell receptor-associated kinase. By blocking SYK, it inhibits downstream B-cell receptor signaling, B-cell activation, and proliferation. It is studied in non-Hodgkin lymphoma.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
TAK-659, CB-659, TAK-659F
Drug type
Small molecule
Targets
spleen tyrosine kinase (SYK)
Mechanism
Inhibitor of spleen tyrosine kinase (SYK)
Pathways
B-cell receptor signaling, B-cell activation, chemotaxis, adhesion and proliferation
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.